Kiev, Ukraine (PRWEB) April 23, 2009
Ekomed LLC ships its first commercial order of Dzherelo (Immunoxel) to Asian market.
In previously published clinical trials in peer-reviewed medical journals, Ekomed's oral immunomodulator Dzherelo (Immunoxel) has been shown to be safe and effective as an adjunct immunotherapy in tuberculosis patients including patients with multi-drug (MDR-TB) and extensively drug resistant TB (XDR-TB). Similar benefits were observed in patients with TB who were also infected with HIV.
Ekomed's Director Mr. Volodymyr Pylypchuk commented: "Thanks to valiant effort of our Australian partner, Zodiac Capital, we are highly satisfied to start sales in our first Asian market country. Dzherelo has been approved there earlier this year as a biologically active dietary supplement by the Mongolian Ministry of Health. Dzherelo is recommended health authorities in Ukraine as an immune adjuvant phyto-pharmaceutical to be used along with TB, HIV and influenza drugs. While market size in Mongolia is relatively small, nevertheless we have now proven that we are capable of expanding to markets beyond the Ukrainian borders. We expect through our partnership with Zodiac to have more approvals and sales in other parts of the world soon".
This year Ekomed has established partnership with Zodiac Capital Limited - a publicly listed investment banking group in Australia. Zodiac has since established joint venture with Stirling Products Limited (ASX:STI) to globally commercialize its phytopharmaceutical products. This deal may potentially assure worldwide global access to Dzherelo (Immunoxel) and other botanical products, especially for needy patients who have limited or no treatment options.
Ekomed LLC is Ukrainian research-driven phyto-pharmaceutical company dedicated to serve patients first. Established 15 years ago, Ekomed discovers, develops, manufactures and markets botanical medicines to address unmet medical needs. The Company undertakes ethically-responsible basic and clinical research efforts to increase adjunct treatment options to the people who need them. Ekomed also strives to publish its research results in reputable medical journals. For more information, visit http://www.ekomed.com.ua
CEO and Scientific Director
pylypchuk (at) bk (dot) ru
Dr. Allen Bain
Zodiac Capital Limited
allen.bain (at) zodiaccap (dot) com
# # #